Next Generation Artificial Tear
Time to Exit
to 36 Months
EternaTear™ is the next generation OTC artificial tear bringing lasting relief to the millions of people who suffer from progressive dry eye, a painful and often debilitating condition. By addressing this large and growing need, this product has the potential for widespread patient adoption while representing a significant opportunity.
EternaTear™ is a group of seasoned healthcare product developers and ophthalmic experts with a proven track record; our team is responsible for developing artificial tears that generate more than $350M in annual revenue. We are currently raising capital to fund formulation refinement, market studies, and manufacturing scale-up then work with a strategic partner to bring EternaTear to market within 30 months.
Time to Exit
to 48 Months
- Ophthalmic surgeon designed next generation refractive implant
- Patented implant & procedure developed to fit the Skill Set of cataract surgeons
- Optics designed to address Myopia, Hyperopia, Astigmatism with Presbyopia,
- Proven (30+ years) intraocular implant location
- Unique & patented implant design to be easily removable or adjustable in-situ
MED1 Ventures LLC.
San Francisco, CA
Email [email protected]